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Abstract One of the most crucial concerns of cancer research
pertains to the differences between the neoplastic cells in
tumor specimens in vivo and their counterparts in cell lines.
The huge amount of results deposited in cancer genetic data-
bases allows to address this issue from a wider perspective.
Our analysis of the Sanger Institute Catalog Of Somatic
Mutations In Cancer (COSMIC) database v61 showed a lower
percentage of homozygous mutations in a group of tumor
suppressor genes in surgical samples (in vivo) in comparison
to their frequency in cell lines (in vitro). Similarly, the muta-
tions resulting in the lack of protein (e.g., nonsense mutations
or whole gene deletions) of several tumor suppressor genes
(TSGs) were more frequently observed in vitro than in vivo. In
this article, we suggest two potential explanations of these
data. Firstly, TSG heterozygous mutations resulting in the
modified protein (e.g., missense mutations) may be gradually
(when the specific molecular context is achieved) changed to
homozygous mutations resulting in the lack of protein during
carcinogenesis. Secondly, among different independent path-
ways of tumorigenesis, those leading to homozygous nonsense
mutations are characteristic for cells which are more efficiently
stabilized in vitro. To conclude, these observations may be
interesting for researchers workingwith cell line in vitromodels
illustrating the extent to which they reflect the tumors in vivo.
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Introduction
It is an obvious fact that cancer cell lines bear only a partial
resemblance to their origin. This issue has been addressed
many times [1–6]; however, thus far, no practical guidelines
on how to address this incongruity have been proposed,
despite the fact that the basic and preclinical research is to a
high extent based on cell line analysis (mostly due to the lack
of a better model for a large scale use). We have already
described the discrepancies in the TP53 mutational profile
between surgical samples and cell lines [7]. Moreover, we
have recently reported differences in the status of several
tumor suppressor genes (TSGs) between glioma cancer cell
lines and surgical specimens [8]. Since a better model is not
available, recognizing such differences might facilitate the
adequate result interpretation, and thus, may be useful in
various research projects from comparative biology studies
to in vitro drug testing. Therefore, we decided to per-
form a comparison of in vivo and in vitro mutational
profiles for other tumor suppressor genes. This would
be the next step in understanding the discrepancies
between the surgical samples and cell lines both in the
frequency of homo- and heterozygous mutations and in
their effect on protein sequence and structure.
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Currently, the foundations of oncology are based on
Knudson hypothesis (two-hit hypothesis), according to which
tumorigenesis requires the elimination of both alleles of given
tumor suppressor gene [9]. However, this model does not
recognize the influence of the first allele elimination on cell
biology. The exceptions to this pattern, such as the single-
heterozygous mutations of TP53, APC, or PTEN in tumor
samples, are usually explained as a consequence of
dominant-negative effect (DNE), gain of function (GOF),
and haploinsufficiency. Recently, Berger et al. proposed an
extension of the two hit model, the continuum/quasi-
sufficiency model, suggesting that one allele elimination/
mutation is sufficient to importantly influence cell biology
and certain genes, such as PTEN, can be entirely eliminated
only at the latest stages of carcinogenesis, since their action
temporarily protects preneoplastic cells against senescence/
apoptosis [10]. This extended model inspired our analyses,
since we assumed that cancer cell lines represent the most
advanced stages of carcinogenesis. Furthermore, various neo-
plastic cells require special conditions to survive in vitro, for
example, those with IDH1 mutation or EGFRvIII [6, 11]. All
these premises encouraged us to inquire if (andwhy) the status
of tumor suppressor genes differs between surgical tumor
specimens and cell lines.
Materials and methods
The mutation frequency and microsatellite instability (MSI)
data was extracted from the Sanger Institute Catalog Of So-
matic Mutations In Cancer (COSMIC) database (v61 release)
which gathers information on somatic mutations taken from
the literature and in-house sequencing in human tumor sam-
ples and tumor cell lines [12–15]. For each gene in the
database, the frequency of normal and mutated samples was
extracted. Moreover, the mutated samples were divided into
groups according to mutation zygosity (homozygosity, het-
erozygosity) and type (Table 1). Two main mutation groups
were distinguished: mutations modifying or partially
abolishing the protein function (mostly missense mutations)
and mutations completely abolishing the protein function
(mostly nonsense mutations and whole gene deletions)
(Table 1). Splicing site mutations were not classified
into either group because of their usually unpredictable
effect on protein structure and function. The analyses
were performed for each gene with Fisher’s exact test
for 2×2 contingency tables calculated with Matlab
2010b (Mathworks) and R 2.15.1 package. The analysis
comprised the comparison of homo- versus heterozy-
gous mutations and those partially versus completely
abolishing the protein function mutations in all their
possible combinations.
Results
Six hundred seventy cancer-associated genes were analyzed in
142,961 samples (137,708 tumor samples and 5,253 cell lines).
The analysis of the summarized data (Supplementary tables)
revealed the significant discrepancies in the frequencies of
different mutation types between the surgical samples and cell
lines. In oncogenes, as expected, there are almost no mutations
resulting in the lack of protein and the proportions of missense
heterozygous and missense homozygous mutations are
retained in cell lines (exemplary data in Table 2: oncogene).
In TSG, we observed two distinct recurrent patterns: a signif-
icant increase in the rate of homozygous mutations with the
retention of the missense/nonsense proportion in cell lines or a
simultaneous increase of the proportion of both homozygous
and nonsense mutations in cell lines. TP53 is an exemplary
gene following the first pattern. In tumor samples, the frequen-
cies of heterozygous and homozygous mutations are compa-
rable (both for missense and nonsense), while the homozygous
mutations are dominant in cell lines (the missense/nonsense
proportion was retained; data and results of the statistical
analyses in Table 2: classical two hits). Moreover, RB1, NF1,
NOTCH1, and PTEN presented similar changes. The second
pattern may be exemplified by the SMAD4 gene, for which the
proportion of nonsense homozygous mutations significantly
increases in cell lines, while that of other mutation types
decreases. For CDKN2A and APC, the mutation proportions
were initially (in tumor samples) strongly shifted towards
nonsense homozygous; however, the increase of this mutation-
al type with the subsequent decrease of the other types of
mutations was statistically significant. BRCA2, SOCS1,
STK11,MSH6, and SMARCA4 followed such a pattern as well
(Table 2: three hits). Furthermore, we observed a group of
genes for which the proportion of nonsense homozygous mu-
tations in tumor samples was similar or higher than in the
Table 1 Classification of mutation type on the basis of the effect on
protein structure and function
Modified protein (mutations
modifying or partially abolishing
the protein function)
Complex, deletion in frame




No protein (mutations completely







Splicing site mutations were not classified into any of group, because of
unpredictable effect on protein structure and sequence
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previouslymentioned genes in cell lines. No further increase of
this proportion was observed in cell lines; however, this may
imply that such genes follow a similar pattern, but the process
is already advanced in tumor samples (Table 2: three hits/final
stage). Finally, we observed several less commonly analyzed
genes which may potentially be classified as following the
second pattern; however, the number of described samples
was not large enough for a reliable analysis (Table 2: three
hits/small group).
Since the number of cases with the reported status of
zygosity was relatively low, we performed an additional
analysis of the proportion of homo-/heterozygous and
missense/nonsense mutations separately to verify the
observed discrepancies in more numerous groups. In
most genes, the results of both analyses were concor-
dant (data in Table 3). Two of the genes initially clas-
sified as following the first pattern (PTEN and RB1)
showed a statistically significant increase in the propor-
tion of nonsense mutations in cell lines in comparison
to tumor samples. On the other hand, for two genes
classified as following the second pattern, (SOCS1 and
MSH6) the increase of the proportion of nonsense mu-
tations in cell lines was not observed. In the genes
potentially following the second pattern, the analysis
of wider groups implies the increase in the proportion
of homozygous and nonsense mutations; however, the
statistical analyses do not confirm its significance.
The analysis of microsatellite data from 810 cell lines and
720 primary samples revealed that the frequency of MSI was
moderately higher in the former. High-frequency MSI
(MSI-H) was detected in 66 cell lines and in 36 primary
samples (8 vs. 5 %, p=0,014). Any MSI (including high- and
low-frequency MSI-L) was detected in 106 cell lines and in 69
primary samples (13 vs. 8.5 %, p=0.036) (Table 4).
Discussion
In general, it is well known that cancer cell lines cannot
be seen as a direct representation of the tumors; how-
ever, the extent of the differences between them may be
underestimated. A deep analysis of mutation databases offers
insight into this issue from another perspective. The presented
study showed that homozygous mutations of many tumor
suppressor genes are significantly more frequent in cell lines
than in tumor samples. Similarly, nonsense mutations of such
genes occur more frequently in vitro than in vivo. The quasi-
sufficiency hypothesis proposed by Berger et al. offers a
partial explanation for these discrepancies [9] (justifying the
higher incidence of single heterozygous mutations in tumor
samples, but not the preference of cell lines towards nonsense
mutations). PTEN is an exemplary gene with such character-
istics. Preneoplastic cells require a heterozygous mutation of
this gene (with its function partially retained) during the early
stages of carcinogenesis, as the cells without PTEN activity
become senescent or die. Apparently, the hyperactivation of
the PI3K pathway may be unfavorable at the early stages of
carcinogenesis [16]. Most authors suggest that the complete
PTEN elimination requires a prior neutralization of the genes
required for oncogene-induced senescence (e.g., TP53,
CDKN2A) [17–19].
Both missense and nonsense mutations of the PTEN
gene almost equally eliminate the phosphatase activity of
the protein; thus, the gradual change from missense het-
erozygous to nonsense homozygous would not be expect-
ed in this case [20]. On the other hand, genes such as
BRCA2 and SOCS1 show the complex differences be-
tween surgery samples and cell lines—a significantly
higher frequency of homozygous and nonsense (i.e.,
resulting in the complete lack of protein) mutations in
the latter (Table 2). For such genes, we propose the “three
hit” model (Fig. 1a). At the initial stages of carcinogene-
sis, a missense TSG mutation is sufficient/optimal through
altering (yet not completely eliminating) the protein func-
tion. Next, a nonsense mutation is generated within the
other allele. Finally, the allele with the missense mutation
is deleted, causing the lack of protein. Other forms of
in vivo changes are also possible, e.g., the missense
mutation may be directly changed into a nonsense one etc.
These data may also offer an alternative explanation, as-
suming that among the multiple independent carcinogenic
pathways, these with nonsense mutations are more adaptable
in vitro and allow for more efficient cell line stabilization. This
may refer both to intratumoral heterogeneity and to differ-
ences between cases (Fig. 1b, c). Therefore, cell lines would
represent only a subgroup of cells/cases observed in vivo.
Here, the transformation into the more advanced tumor stages
is not accompanied by the missense to nonsense change.
Nonetheless, still, the nonsense mutations may hypothetically
cause some biological changes associated with the ease and
effectiveness of cell line stabilization, e.g., the cells isolated
from tumors with nonsense mutations may be more prolifer-
ative. CDKN2A is an exemplary gene whose molecular char-
acteristic supports the in vitro adaptation hypothesis.
These hypotheses may seem mutually exclusive; however,
both may be partially responsible for the observed differences.
Still, irrespective of the underlying mechanism, such discrep-
ancies are an incentive to consider the respective genes as
following the quasi-sufficiency hypothesis.
Finally, we inquired whether the defective DNA dam-
age response and repair mechanisms might be responsi-
ble for the observed differences in mutational profiles.
For that purpose, we compared the MSI detection rates
in cell lines and primary samples. Although the differences
were statistically significant, microsatellite instability may not
be the sole explanation of the observed results, due to its
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generally low detection rates (Table 4). Nonetheless, it may be
one of the aspects affecting the cell line stabilization
effectiveness.
The database analysis provides an additional argu-
ment that average cells from a cell line are more ad-
vanced in tumorigenesis than average cells from the
corresponding surgical sample, e.g., the frequencies of
detected TSG mutations are much higher in cell lines;
however, the more thorough analysis of cell lines has to
be emphasized.
In conclusion, we report the preferential character of
nonsense mutations of TSGs in the most advanced cancer
cells. Apparently, during the early stages of tumorigenic
transformation, the complete elimination of many TSG
may be lethal or otherwise unfavorable and becomes
possible only when the required cellular/molecular con-
text is achieved. Our hypothesis of “three hits” is a mod-
ification of the “continuum” model by Berger et al. [10].
Clearly, the potential transformation of missense to non-
sense mutations during carcinogenesis requires more data.
Alternatively, the presented data may be explained by the
hypothesis that cell lines originating from tumors/cells
with nonsense mutations are more easily stabilized in
comparison to those with missense mutations. The differ-
ences in the mutational characteristics of TSG between
tumor samples and cell lines may indicate the lack of the
appropriate in vitro representation of tumors in vivo,
which is particularly important from the drug testing
perspective.
This study was supported by the National Science
Center Grant No. 2011/01/B/NZ4/07832. Calculations in
this paper have been carried out within Upper Silesian
Center for Scientific Computational Science and Engineering
(POIG.02.03.01-24-099/13).
Fig. 1 The hypotheses potentially explaining the differences in muta-
tional profiles. a In vivo transformation of missense into nonsense muta-
tions; this process may occur through various mechanisms, for example, a
missense mutation of one allele is followed by a nonsense mutation of the
other alleles and next by a deletion of the allele with the missense
mutation. Missense mutations are marked as yellow spots, nonsense
mutations as blue ones. b In vitro selection of tumor specimens which
may give rise to stabilized cell lines. Obviously, the mutational status of a
single gene may not determine the stabilization efficiency; however, the
cumulative influence of all mutations may affect the probability of the
successful cell line stabilization. The color of the tumor represents the
mutation type of given gene (legend in the top right-hand corner), which
is further reflected by the color of the cap of the respective culture flask.
Stabilized cell lines are marked as yellow bottles with underlined labels;
the others are marked as orange bottles with normal labels. c In vitro
selection of cells within a tumor specimen which may give rise to a
stabilized cell line. Again, within a heterozygous tumor the cells with
certain molecular profiles may be more predisposed to the stabilization as
a cell line. The color of the cells within tumors represents the mutation
type of given gene (legend in the top right-hand corner), which is further
reflected by the color of the cap of the respective culture flask. Stabilized
cell lines are marked as yellow bottles with underlined labels; the others
are marked as orange bottles with normal labels
Table 4 A comparison of microsatellite instability frequency in human
cancer cell lines and surgical samples. Fisher’s exact test results
MSS MSI
MSI-H MSI-L Total
Tumor 651 36 33 69
Line 704 66 40 106
MSI-H vs. others p=0.01384 Any MSI vs. MSS p=0.03624
MSS microsatellite stability, MSI microsatellite instability, MSI-H high-
frequency microsatellite instability (detected in at least 2 markers),MSI-L
low-frequency microsatellite instability (detected in 1 marker)
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